Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.9 million.

The offering price per share of Common Stock is $0.795 and per Warrant is $0.005. The transactions consisted of the sale of 3,625,000 shares of Common Stock in the registered direct offering and Common Warrants to purchase 3,625,000 shares of Common Stock in the private placement with an exercise price of $0.84 per share.

Aggregate gross proceeds to the Company are expected to be approximately $2.9 million. The transactions are expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offerings, together with its existing cash, cash equivalents, restricted cash and investment grade securities, including accrued, for general corporate purposes and working capital.